Dateline City:
KENILWORTH, N.J.
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
approved BRIDION (sugammadex) Injection 100 mg/mL
(equivalent to 108.8 mg/mL sugammadex sodium) for the reversal of
neuromuscular blockade (NMB) induced by rocuronium bromide and
vecuronium bromide in adults undergoing surgery.
Language:
English
Contact:
MerckMedia Contacts:Pamela Eisele, 267-305-3558Doris Li, 908-740-1903orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879
read more